NOV 2014 ARTICLE LIST >>
PharmaTutor (November- 2014)
ISSN: 2347 - 7881
(Volume 2, Issue 11)
Received On: 26/08/2014; Accepted On: 07/09/2014; Published On: 01/11/2014
AUTHORS: Patel Divya A*., Varodiya Priyanka S., Raj Hasumati A.
Department of Quality Assurance, Shree Dhanvantary Pharmacy College,
Kim, Surat, Gujarat, India
divyapatel388@gmail.com, drharaj@yahoo.com
ABSTRACT:
This review article presents the pharmacology of combined edaravone and argatroban therapy especially in acute ischemic stroke. Edaravone (MCI-186) is a free radical scavenger, a novel neuroprotective agent. Argatroban is a selective thrombin inhibitor. The antithrombotic agent was used in acute cerebral infarction. If the antithrombotic agent is administered in large quantities, the condition of patient become worse by occurrence of adeverse effect of cerebral haeorrhage. The use of edaravone in combination with antithrombotic agent has been proved to provide beneficial effect in acute ischemic stroke as edaravone has no influence to coagulation of blood and platelets aggregation. The combination therapy has fewer hemorrhagic adeverse effect. The mechanism of argatroban and edaravone is quite different. Argatroban, an anti-coagulant drug, directly improves the microcirculation of ischemic brain tissue while edaravone could indirectly attenuated brain edema by protection of endothelial cells damaged by free radicals generated after ischemic insult. The combination of both would have reciprocal and enhanced neuroprotective effects against ischemic insult. Both the drugs were approved by Japanese government and has been used in acute brain infarction in japan. The main objective of this review article is to provide pharmacological information of combined therapy of edaravone and argatroban to researcher in development of combined dosage form of this.
How to cite this article: DA Patel, PS Varodiya, R Hasumati; A Review on Pharmacology of Combined Edaravone and Argatroban Therapy in Acute Ischemic Stroke; PharmaTutor; 2014; 2(11); 42-49
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. Shaheen E Lakhan, Annette kirchgessner and Magelalena Hofer ; Review IInflammation mechanism in ischemic stroke : therapeutic approaches;Journal of Translational medicines; Nov, 2009, 7-97.
2. Edaravone Drug Info.(database available on internet):Chemical Book. Available from: chemicalbook.com/ProductMSDSDetailCB1287462_EN.htm
3. Edaravone Drug Info.(database available on internet):Lookchem. Available from: lookchem.com/Edaravone/
4. Toshiaki W, Munenori T, Satoru T. The Novel Antioxidant Edaravone: From Bench to Bedside. Cardiovascular Therapeutics; 20098, 26: 101–114.
5. Doherty AM. Annual Reports in Medicinal Chemistry. Boston: Academic Press; 2002, 37.
6. Watanabe T. et al. Research and development of the free radical scavenger edaravone as a neuroprotectant. Yakugaku Zasshi (in Japanese); 2004, 124(3): 99–111.
7. Higashi Y, Jitsuiki D, Chayama K, Yoshizumi M. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases. Recent Patents on Cardiovascular Drug Discovery; 2006, 1(1):85–93.
8. Yoshida H. et al.Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Reviews; 2006, 12(1):9–20.
9. Yuan WJ. et al. Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons. BMC Neuroscience; 2008,9:75.
10. Kawasaki T. et al. Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum. European Journal of Pharmacology; 2006, 542(1-3): 92–99.
11. Kawasaki T. et al. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced neurotoxicity in the substantianigra but not the striatum. The Journal of Pharmacology and Experimental Therapeutics; 2007, 322(1):274–281.
12. Yokoyama H. et al. Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice. Journal of Neural Transmission; 2008, 115(6):831–842.
13. Yokoyama H. et al. Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice. Metabolic Brain Disease; 2008, 23(3):335–349.,
14. Available from : gsksource.com/gskprm.
15. Tripathi.K.D , Essential of medical pharmacology ; 6 th edition ;594
16. Escolar G, Bozzo J, Maragall S; Argatroban a direct thrombin inhibitor with reliable and predictable anticoagulant action; Drug today 2006, Apr; 42(4), 223-236
17. Young-Jian Jin, Tatsuo Mimma, Valerica Raicu, Kae Chang Park, Keiji Shimizu; Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils; Neuroscience Research 43(2002) 75-79.
18. Keiichi Tesseikai, Katsumi C/o; Drugs comprising combination of anti thrombotic agent with pyrazolone derivative; Patent EP1437137B1.
19. Combination therapy for Acute ischemic stroke study group; Edaravone and argatroban stroke therapy study for acute ischemic stroke; clinicaltrials.gov.
.png)
